Smith & Nephew Snats (SNN) Gets a Hold from Berenberg Bank
In a report released yesterday, Sam England from Berenberg Bank maintained a Hold rating on Smith & Nephew Snats, with a price target of $34.91. The company’s shares closed yesterday at $33.08.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
England covers the Healthcare sector, focusing on stocks such as Smith & Nephew Snats, ConvaTec, and Carl Zeiss Meditec. According to TipRanks, England has an average return of -1.1% and a 50.82% success rate on recommended stocks.
Smith & Nephew Snats has an analyst consensus of Hold, with a price target consensus of $34.46, implying a 4.17% upside from current levels. In a report released on January 13, Canaccord Genuity also reiterated a Hold rating on the stock with a $34.00 price target.
Based on Smith & Nephew Snats’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.99 billion and a net profit of $295.65 million. In comparison, last year the company earned a revenue of $2.83 billion and had a net profit of $214 million
Read More on SNN:
Disclaimer & DisclosureReport an Issue
- Smith+Nephew Closes US$450m Integrity Orthopaedics Deal to Bolster Sports Medicine Portfolio
- Smith & Nephew: Strategic Integrity Orthopaedics Acquisition and Underappreciated Sports Medicine Growth Support Buy Rating
- Smith+Nephew to Acquire Integrity Orthopaedics to Bolster Shoulder Repair Portfolio
- Smith & Nephew’s PICO Venous Leg Ulcer Study Terminated: What Investors Should Know
- Smith & Nephew Updates Share Capital and Voting Rights as of Year-End 2025
